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Abstract 
Objective: The aim was to identify factors explaining inconsistent observations concerning 
the efficacy of intra-articular hyaluronic acid compared to intra-articular sham/control, or 
non-intervention control, in patients with symptomatic osteoarthritis, based on randomized 
clinical trials (RCTs). 
Methods: A systematic review and meta-regression analyses of available randomized trials 
were conducted. The outcome, pain, was assessed according to a prespecified hierarchy of 
potentially available outcomes. Hedges‘s standardized mean difference (SMD [95%CI]) 
served as effect size. REstricted Maximum Likelihood (REML) mixed-effects models were 
used to combine study results, and heterogeneity was calculated and interpreted as Tau-
squared and I-squared, respectively. 
Results: Ninety-nine studies (14,804 patients) met the inclusion criteria: Of these, only 71 
studies (72%), including 85 comparisons (11,216 patients), had adequate data available for 
inclusion in the primary meta-analysis. Overall, compared with placebo, intra-articular 
hyaluronic acid reduced pain with an effect size of -0.39 [-0.47 to -0.31; P<0.001], combining 
very heterogeneous trial findings (I2=73%). The three most important covariates in reducing 
heterogeneity were overall risk-of-bias, blinding of personnel and trial size, reducing 
heterogeneity with 26%, 26% and 25%, respectively (Interaction: P≤0.001). 
Adjusting for publication/selective outcome reporting bias (by imputing ―null effects‖) in 24 
of the comparisons with no data available reduced the combined estimate to -0.30 [-0.36 to -
0.23; P<0.001] still in favor of hyaluronic acid. 
Conclusion: Based on available trial data, intra-articular hyaluronic acid showed a better 
effect than intra-articular saline on pain reduction in osteoarthritis. Publication bias and the 
risk of selective outcome reporting suggest only small clinical effect compared to saline. 
Keywords:  Osteoarthritis, Pain, hyaluronic acid, efficacy, bias, inconsistency. 
 
 
 
 
Abbreviations: 
REstricted Maximum Likelihood (REML), Osteoarthritis (OA), Intra-articular (IA), Hyaluronic Acid (HA), Intra-articular 
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Systematic Reviews and Meta-Analyses (PRISMA), American College of Rheumatology (ACR), Osteoarthritis Research 
Society International (OARSI), European League Against Rheumatism (EULAR), Intention to treat (ITT), Standard 
deviation (SD), Standard errors (SE), Confidence intervals (CI), Differences in means (MD), Standardized mean difference 
(SMD), Minimal important difference (MID), Tau-squared (T2), Serious adverse events (SAE), Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC)  
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1. Introduction 
Although osteoarthritis (OA) is the most common musculoskeletal condition and is a major 
cause of pain, disability, and loss of quality of life (1), there is no well-established disease or 
structure-modifying therapy.  Current treatments for OA aim at relieving symptoms (mostly 
pain) and improving function. Because no single intervention is entirely effective, most 
programs combine non-pharmacologic and pharmacologic therapies (2, 3). An often used 
pharmacologic therapy in OA involves intra-articular (IA) hyaluronic acid (HA), sometimes 
referred to as viscosupplementation (4-6). From the current debate there are significant 
controversies concerning the potential effect of IAHA in the treatment of OA. 
 Several systematic reviews have suggested that IAHA has only a marginal, if 
any, effect compared with placebo (7-11), whereas others have reported robust efficacy (12-
17). The premise for performing a meta-analysis is to combine the results of all relevant trials 
addressing the same clinical question to give a more precise, and hopefully unbiased, 
estimate of the treatment effect. However, if this combination of trials builds on serious 
inconsistency, a summarized estimate may have no interpretable meaning. Judgment of the 
extent of heterogeneity is based on similarity of point estimates, extent of overlap of 
confidence intervals, and statistical criteria including tests of heterogeneity and inconsistency 
indices (18). When inconsistency is large and unexplained, rating down the quality of 
evidence is appropriate, particularly if some studies suggest substantial benefit whereas 
others indicate no effect. By investigating the sources of heterogeneity among included trials, 
researchers can identify sources of bias in the summary effect measure (19). Such inquiries 
may also yield insights into whether certain patients are more likely to experience benefits of 
a treatment. 
To explain the controversy around the use of IAHA for OA, while emphasizing the need for 
evidence-based research (20, 21), a protocol was initiated for the systematic review of 
existing evidence with an AMSTAR assessment (22) (See Appendix 1).  
The objective was to evaluate evidence that assesses the efficacy and safety of IAHA in 
patients with symptomatic OA by carrying out a systematic review and meta-analysis to 
explore potential reasons and contextual factors which may explain the discrepant trial 
results. 
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2. Materials and Methods 
 
The search for the systematic review at the meta-analysis was performed according to the 
recommendations in The Cochrane Handbook for Systematic Reviews of Interventions (23), 
and the findings were reported according to the ―Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses‖ (PRISMA) statement (24). The methods of analysis and the 
inclusion criteria were specified in advance and registered in the international Prospective 
Register of Systematic Reviews (PROSPERO registration no. CRD42014007284; the 
protocol is available in Appendix 1). 
 
2.1 Eligibility criteria 
Randomized and quasi-randomized clinical trials comparing IAHA with IA physiological 
saline injection or with non-intervention control in adults diagnosed with OA according to 
American College of Rheumatology (ACR) criteria (25) or equivalent were considered 
eligible for inclusion in the meta-analysis. No restrictions were applied concerning race, sex, 
joint, type of HA, molecular structure, molecular weight, number of injections per cycle, 
number of cycles, or follow-up duration. Studies with an active control group, and IAHA 
following a surgical procedure were excluded. 
 
2.2 Information sources and search strategy 
Two reviewers (MJ and HBa) searched the following bibliographic databases: MEDLINE via 
PubMed from 1966, EMBASE via Ovid from 1974, Web of Science via Web of Knowledge 
from 1960 and the Cochrane Library from 1998 all upto 10
th
 November 2014 (Appendix 1). 
Manual searches, including scrutinizing of reference lists of identified systematic reviews 
were performed. The last 2 years of specialist journals and conference proceedings, including 
ACR, OARSI and EULAR were also searched. Unpublished trials were sought by 
correspondence with experts in the field of OA and IAHA and by searching in 
http://clinicaltrials.gov and http://apps.who.int/trialsearch/. No language, publication date or 
publication status restrictions were imposed. The literature search for potentially eligible 
studies (conducted by MJ and HBa) was supervised by an experienced research librarian and 
documentalist (EMB) (26). 
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2.3 Study selection 
Eligibility assessment was performed independently by two reviewers (MJ, HBa), who 
screened all relevant references by title and abstract. Studies not fulfilling eligibility criteria 
were rejected. Reports of the remaining studies were read in full text. Disagreement was 
resolved by consensus or with help from a third reviewer (RC/HBl).  
 
2.4 Risk of bias in individual studies 
Study quality (i.e., internal validity) and the potential risk-of-bias in the eligible trials were 
included in the meta-analysis (27, 28). Two reviewers (MJ, HBa) independently assessed the 
study quality using the risk-of-bias tool recommended by Cochrane Collaboration  (23). The 
following risk-of-bias items were included: (1) sequence generation; (2) allocation 
concealment; (3a) blinding of patients; (3b) blinding of personnel; (4) incomplete outcome 
data addressed (i.e., using an appropriate intention to treat (ITT) population; a modified ITT 
was considered adequate if dropout took place before treatment was initiated if judged that 
the blinding had not been broken); and (5) selective outcome reporting, together with other 
bias domains defined as (a) funding and (b) single vs. multi center. 
Each trial was assigned an overall Risk of Bias term: ―Low Risk‖ denoted that all 
domains were reported adequately; ―Unclear risk" defined that at least one domain was 
unclear; and ―High risk‖ denoted that at least one of the domains was inadequate (29). 
Disagreement about the risk-of-bias judgment was resolved by consensus, and if agreement 
could not be reached, a third reviewer (RC) was involved in order to reach consensus of the 
overall risk-of-bias. Further details are available in the protocol (Appendix 1). 
 
2.5 Data collection process and data items 
A customized data extraction sheet was developed, pilot-tested, and refined accordingly. The 
two reviewers (MJ, HBa) independently extracted data. Disagreement was resolved by 
consensus and if agreement could not be reached a third reviewer (RC) was involved to reach 
consensus. Extracted information included the following contextual factors: (1) study 
information and characteristics (publication year, author, publication source, publication 
status and trial sponsors, inclusion and exclusion criteria, diagnostic criteria, average age, 
number of women and average duration of symptoms); (2) characteristics of the methods 
(study design, number of participants (randomized/analyzed)), trial size (<100 in each group, 
or more), study duration, use of sham/control; (3) characteristics of the intervention (joint, 
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type of HA, dose, average molecular weight or structure; number of cycles and injections, 
ultrasound monitored injections). 
Results were extracted on the ITT population - including N, mean and standard 
deviation (SD), where possible, for each group. In cases where SD was not available, SD was 
calculated on the basis of standard errors (SE), confidence intervals (CI) or P-values for 
differences in means (MD) between the intervention and control group as recommended by 
the Cochrane Collaboration (23), or ultimately data were obtained from figures. If only the P-
value was reported, the estimated effect size based on the ―statistical significance‖ and 
number of participants was recovered (30). If the exact P-value was not reported but the result 
was reported as statistically significant (e.g., P<0.05), the effect size was calculated by using 
the cut point used in the individual trials to report statistical significance (e.g., P=0.05), as 
recommended by the Cochrane Collaboration (23). If effect sizes could not be calculated, the 
reviewers attempted to contact authors for additional data. The priority in data extraction was 
given in the following order (1) follow up data and (2) change from baseline; i.e. if mean 
values follow-up data was unavailable, mean change score was extracted (23). 
The selection of the appropriate outcome domains was based on the recommendations 
from OMERACT (31), where pain is considered as primary outcome in OA (32). When data 
were reported based on more than one outcome measurement instrument, the proposed 
hierarchical list of patient-reported outcomes for meta-analyses of knee OA trials was used 
(33, 34). When outcomes were reported at several time points, preference was given to data 
assessments conducted 3 months (range: 8-16 weeks) following the completion of the 
intervention. If assessments were not available, the long-term follow-up, defined as 6 months 
from completion of intervention (range: 4-7 months) was extracted. If none of the pre-
specified time points were available, data were extracted from the end of intervention to 7 
weeks following the completion of the intervention (range 0-7 weeks). 
 
2.6 Statistical analysis 
The effect size was expressed as a standardized mean difference (SMD), defined by dividing 
the difference in means by the pooled standard deviation (SD). The primary advantage of the 
SMD is the fact that it provides a common metric (35); a minimal important difference (MID) 
of 0.2 SMD was pre-specified, as referred to in Behavioral Science as the lower boundary of 
a small effect (36). A negative effect size (SMD) indicated a beneficial (i.e., pain reducing) 
effect of the intervention group compared with control. As the Cohen‘s SMD is biased in 
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small samples, Hedges‘s g was applied in the meta-analysis treating the variance as an 
estimate (37). Trials with multiple IAHA arms were handled as individual trials (i.e., 
mutually independent randomized comparisons) dividing the control group equally according 
to the number of treatment arms in order to avoid double counting of patients (23). 
 The random effects model was used for the primary meta-analysis owing to the 
a priori expected inter-trial heterogeneity (38). The forest plots were reviewed and the inter-
trial heterogeneity was examined with the Cochran Q-test and evaluated by the inconsistency 
I
2
 index (39). Fixed-effect analysis was applied for the purpose of exploring small-study bias, 
which also involved assessing funnel plots and performing Egger‘s test (40). Furthermore, an 
adjustment strategy for selective outcome reporting was made by imputing data from ―null 
findings‖ for the studies that did not report adequately on pain (41), based on the assumption 
that they did not have any clinical impact. Summary estimates of treatment effect from 
random-effects models correspond to an average effect across all studies without being able 
to ―penalize‖ the certainty around the estimate from substantial heterogeneity. To 
quantitatively incorporate the heterogeneity, 95% prediction intervals were estimated, of the 
likely effect in an individual setting i.e. covering the likely finding from any new trial (42). 
 Anticipating substantial heterogeneity, several a priori defined stratified 
analyses of the primary outcome were performed according to the following trial 
characteristics: risk-of-bias domains (23), type of sham/control intervention, single-center vs. 
multi-center trial, publication status, funding, number of cycles, number of injections, follow-
up duration, molecular weight, molecular structure (cross-linked vs. non-cross-linked), 
ultrasound guidance, joint (knee, hip, other [including ankle, shoulder, hand, 
temporomandibular joint]), and trial size. Available studies were stratified according to trial 
characteristics and continuous variables at trial level, after which analyses were performed, 
fitting multiple Restricted Maximum Likelihood (REML)-based meta-regression models (43). 
A priori a ―relevant study-level covariate‖ was defined as a covariate that would decrease the 
between-study variance was defined (19, 44), (estimated Tau-squared [T
2
]) as a consequence 
of inclusion in the (mixed effects) statistical model (30, 45). Analyses were performed using 
STATA V.12 (Stata Corp, Texas, USA). 
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3. Results 
3.1 Search results 
The literature search identified 3,021 references leaving 1,963 references after removal of 
duplicates. The titles and abstracts of these were screened for inclusion (Figure 1). 1768 did 
not fulfill the inclusion criteria leaving 195 references for assessment in full-text, of which 99 
trials, including 115 comparisons and 14,804 patients, met the inclusion criteria (Table 1; i1-
99). Of these studies, 71 were published as full reports (i1-71), 15 were published as abstracts 
(i72-86), and 6 trials were unpublished (i87-92). One trial from Sanofi Aventis (i87) was 
available as a medical report on sanofi.com, and five protocols were identified in 
clinicaltrials.gov and who.int/trialsearch, registered from 2008-2011 and last verified from 
2009-2013. Of these five results, a trial conducted by Ferring Pharmaceuticals (i91) was 
available only on clinicaltrials.gov. It was not possible to locate results or publications from 
the remaining four protocolized trials (i88-90,i 92). An additional seven trials were identified 
by scrutinizing other sources, but results were not located (i93-99). Three of these trials (i96, 
i97, i99) were performed by pharmaceutical companies. Following the data extraction 
procedure, 85 comparisons (11,216 patients) had adequately reported results, described in 71 
trials (72%). Results were not extractable, not located, or unpublished in 30 comparisons 
(described in 28 trials). 
 
3.2 Included studies 
As presented in Table 2, the mean age of the patients in the included trials ranged 
from 38 to 72 years with a median of 62 years, and the mean duration of symptoms ranged 
from 1 to 22 years with a median (of means) being 6 years. The mean number of cycles 
ranged from one to four cycles with a median of one cycle. The mean number of injections in 
each cycle ranged from 1 to 11 with a median of 3 injections. The average duration of follow-
up ranged from 0 to 36 weeks with a median of 10 weeks. The majority of the trials (83 of the 
99 trials) tested the effect of IAHA in patients with OA of the knee. The remaining 16 trials 
were as follows: 5 trials on hip OA (i43, i56, i57, i62, i89), 2 trials on OA in the hand (i49, 
i55), 4 trials on OA in the ankle and foot (i44, i48, i64, i68), 3 trials on temporomandibular 
joint OA (i6, i61, i66) and 2 trials (describing 3 comparisons) on shoulder OA (i46, i70).   
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3.3 Methodological characteristics 
Methodological characteristics in eligible trials were assessed for accuracy. These 
trials are listed in Table 3. Adequate sequence generation was reported in 34 trials (39%); 30 
trials (34%) reported adequate concealment of allocation; 38 trials (43%) were judged to have 
adequate blinding of patients; and 52 trials (59%) were judged having adequate blinding of 
outcome assessor. Twenty-six trials (30%) used an adequate analysis based on the intention 
to treat (ITT) principle. Thirty-seven trials (42%) had adequate outcome reporting. The 
overall risk-of-bias in the individual studies were considered ―Low Risk‖ in 8 trials (9%), 
―Unclear Risk‖ in 16 trials (18%), and ―High Risk‖ in 64 trials (73%). For ―Other risk-of-
bias‖, 6 trials (7%) were reported as being free of industry support, and 44 trials (50%) were 
reported as multicenter trials. 
 
3.4 Pain 
The overall meta-analysis of 85 comparisons revealed that IAHA had an effect size of -0.39 
[-0.47;-0.31; P<0.001], meeting the pre-specified MID (Figure 2). An I
2
 of 73% indicated, 
however, a substantial degree of heterogeneity, which was visually evident from the wide 
scatter of effect estimates with little overlap in their confidence intervals. The potential small-
study bias was examined by using a fixed-effect analysis resulting in a combined SMD of -
0.27 [-0.31; -0.23] (data not shown). To further explore the impact of inconsistency across 
trials, a 95% prediction interval was applied (−0.99 to 0.22): Although most of the prediction 
interval favored IAHA, the interval overlaps zero, predicting that not all individual trials will 
favor IAHA when compared to control. 
The funnel plot depicts evidence of considerable asymmetry (confirmed by an Eggers 
test, P<0.001), indicating a high risk of publication and/or reporting biases (Figure 3). Thus, 
in order to adjust for the possible selective outcome reporting, additional analyses included 
comparisons with number of participants extractable, assigning 24 comparisons null findings 
(i5, i6, i18, i25, i26, i36, i39, i49, i62, i65, i72, i74, i75, i77, i84, i93-99), thereby including 109 
comparisons in total in the analyses. The ―null finding imputation‖ revealed a more modest 
effect size of -0.30 [-0.37;-0.23; P<0.001] - with the 95%CI covering the result from the fixed 
effects model.  
The pre-specified stratified analyses of available trials performed with meta-
regression provided estimates likely explaining some of the heterogeneity (Figure 4). The 
most important study characteristics reducing heterogeneity were overall risk-of-bias, 
blinding of personnel, and trial size: The effect size of low risk-of-bias trials of -0.00 [-
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0.13;0.12] did not reach the MID, whereas the unclear and high risk-of-bias subgroups 
revealed an effect size of -0.81 [-1.19;-0.44] and -0.35 [-0.43;-0.27], respectively, and these 
strata were statistically significantly different (P-value for interaction <0.001). A 
corresponding 25.7% reduction in heterogeneity was seen (change in tau
2
 from 0.14 to 0.11). 
As for blinding of personnel, a distinction between adequate versus unclear and inadequate 
blinding revealed a difference in effect sizes of -0.23 [-0.31;-0.16] for adequate versus an 
effect size for unclear -0.70 [-0.90;-0.50], and for inadequate -0.61 [-0.87;-0.35], indicating a 
potential interaction among strata (P <0.001) with a relevant reduction in heterogeneity (tau
2
 
decreased by 25.7%). Trial size also had an effect on study results with an effect size of -0.57 
[-0.72;-0.42] in trials with fewer than 100 subjects per treatment group compared to larger 
trials showing an effect size of -0.21 [-0.28;-0.13] (P < 0.001). A corresponding relevant 
reduction in heterogeneity of 25.3% was also detected (tau
2 
reduced from 0.14 to 0.11).  
Consequently, the overall risk-of-bias, reported blinding of personnel, and trial sizes 
explained a significant part of the heterogeneity. Other factors leading to a relevant reduction 
in tau
2
 of heterogeneity were (prioritized): multicenter design (17.4%), incomplete data 
addressed (13%), number of injections (12.1%), follow-up duration (12%), and independence 
of industry support (11.7%), all with a significant P-value for interaction (P<0.032). 
Furthermore, the stratified analysis showed an effect size of -0.34 [-0.41; -0.27] for IA 
saline as control vs. IAHA and an effect size for non-intervention control vs. IAHA of -0.70 
[-1.23; -0.26], with a reduction in tau from 0.14 to 0.12 (12.9%), but P-value for interaction 
not being statistical significant. 
In addition a stratified analyses according to the number of high risk-of-bias domains 
as well as low risk-of-bias domains was performed. Apparently, by stratifying according to 
the number of low risk-of-bias domains, the amount of heterogeneity is reduced (tau
2
 reduced 
from 0,142 to 0.128) with a P-value indicating a statistically significant interaction (i.e. the 
effect size vary according to the number of low risk-of-bias domains and the analyses showed 
larger effect size in studies with higher risk-of-bias) (Appendix 2). 
 
3.5 Safety 
The meta-analysis of serious adverse events (SAE) was calculated based on the 71 trials 
included in the main meta-analysis. Sixty-one trials reported on SAE (Figure 5), and 17 of 
these trials reported one or more cases of SAEs observed in each group. The trials that did not 
report SAE are shown in the analyses as ―excluded‖ (i23, i28, i40, i41, i61, i76, i78, i80, i82, 
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i83, i85). Although based on only a minority of the available trials from the pooled analysis 
there was no statistically significant difference between IAHA and control (Risk Difference 
of 0.002 [-0.001;0.005; P=0.28]). 
 
 
4. Discussion 
The overall meta-analysis, including 71 trials, with 85 comparisons, showed a large degree of 
heterogeneity and indications of small-study bias. The main result of the analysis was the 
finding of a small, but clinically relevant, effect of IAHA in patients with OA, showing a 
reduction of pain in accordance with previous meta-analyses (12-17). In contrast, if evidence 
was only based on low-risk of bias studies, no effect of IAHA was detected at all. Meta-
analyses of randomized trials begin as high-quality evidence, but the accumulated evidence is 
frequently downgraded as a result of limitations in study design (e.g., risk-of-bias), 
imprecision of estimates (wide confidence intervals), heterogeneity, indirectness of evidence, 
and publication bias (46). The poor methodological quality and reporting quality of many of 
the included trials (47) added yet another major limitation of studies being inconsistent (18) 
and having substantial risk of publication bias (48). These limitations reduced confidence in 
the estimate, suggesting a downgrade of the quality of evidence to low (49). Further 
downgrading to very low quality of evidence is necessary, because overall risk-of-bias 
reduced some of the observed heterogeneity. Blinding aspects and differences in results from 
large trials compared to smaller trials also reduced heterogeneity and helped to elucidate the 
risk-of-bias. Thus, based on relatively easily accessible data, the true effect is likely to be 
substantially lower than the initially estimated effect size of -0.39 [-0.47 to -0.31]. However, 
various modified models could potentially allow us to increase the ―certainty‖. To a large 
extent an adjustment for the selective reporting is possible (incl. publication bias) by adding 
―null effects‖ for the 24 comparisons ―without data‖. Hence, this meta-analysis with ‗low 
quality evidence‘ was able to present an effect size associated with IAHA in OA patients of -
0.30 [-0.37;-0.23] (95% prediction interval: -0.87 to 0.26), tentatively adjusting for selective 
outcome reporting. 
Controversy over the clinical value of IAHA is fomented by inconsistent results from 
former meta-analyses. Eleven meta-analyses were found and assessed according to AMSTAR 
to be of different methodological quality. Six reviews (12-17) concluded that IAHA was 
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more effective than saline, or placebo; whereas five reviews (7-11) were cautious to conclude 
on the effectiveness or concluded that the effect was not clinically relevant. Among the 
possible explanations for the differences in estimates on benefits is the different pain 
outcomes used in the meta-analyses. This study‘s meta-analysis used the hierarchy of pain 
outcomes based on the responsiveness of the outcome measures (33), whereas former meta-
analyses (7, 10) used other recommended outcome hierarchies (50). In addition, this meta-
analysis included IAHA for OA not only in the treatment of knee joints but also in hip and 
other joints (ankle, foot, temporomandibular joint, shoulder and hand). The literature on 
joints other than the knee is not as robust, and the stratification of joints suggested an effect 
size of -0.13 [-0.40; 0.15] and -0.18 [-0.32;-0.04] for hip and other joints, respectively. One 
possible reason, however, for a lesser effect of injections in other joints than the knee, is the 
uncertainty of placement of the injected substance if not guided by ultrasound (51, 52). These 
results do not support an effect of IAHA injections in other joints. On the other hand, the 
notion of more precision in the injections into the knee substantiates the IAHA use for this 
joint. Accordingly, the effect size for knees, when excluding other joints, improved to -0.43[-
0.52;-0.34]. Furthermore, differences in time points could explain some of the discrepancies 
among the meta-analyses, an explanation that corresponds to the findings from Campbell and 
colleagues (53). In this meta-analysis, the pre-specified timepoint hierarchy found the largest 
effect in trials with short-term follow-up, which is consistent with other meta-analyses 
showing the largest effect size at 8 weeks (12, 13, 16). In contrast, other meta-analyses 
demonstrated the significantly greatest effect at 3 and 6 months (7, 8). 
The choice of comparator for IAHA could also be of great importance for the estimate. The 
present meta-analysis compared IAHA with saline or non-intervention control as a 
comparator. Furthermore, this review excluded trials performing IAHA as a part of post-
operational treatment and where the included patient group had a mixture of diagnoses, 
whereas other meta-analyses also included post-surgical IAHA and mixed diagnoses as a 
comparator (7, 9, 10). When stratifying, this meta-analysis showed an effect size of -0.34 [-
0.41; -0.27] for IA saline vs. IAHA injections, and an effect size for non-intervention control 
vs. IAHA of -0.70 [-1.23; -0.26], the latter not being statistically significant. These results are 
consistent with findings from a study looking at the placebo effect, where the effect size 
decreased when compared to placebo administered through needles or injections (i.e., 
placebos of acupuncture) (54). Most of the trials in this meta-analysis used physiological 
saline as the comparator. The effect of saline injection for OA of the knee is unclear but was 
shown as effective as an NSAID in an IAHA trial (i19). Furthermore, a recent OA trial of IA 
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corticosteroids compared to IA saline showed no superior effect of IA corticosteroids over IA 
saline (55). If saline is considered a treatment and not a placebo, IAHA would be considered 
as having a slightly better effect than IA saline on pain in patients with OA. 
The meta-analysis of Lo et al. (10) found a better effect of high molecular weight 
IAHA above 6000 kDa than the lower molecular IAHAs, but this was limited by 
heterogeneity among trials such that definitive conclusions were not possible. This agrees 
with the findings in this meta-analysis where trials with high molecular weight IAHA showed 
a significantly better effect of IAHA than trials using lower molecular weight HA, also 
revealing a large inconsistency among trials. The findings are very relevant in clinical 
practice and for future research. 
Compared to the findings in available studies with an effect size of -0.39 (which 
corresponds to -1.56 on WOMAC pain, ranging from 0 to 20, and -0.98 cm change on a 10-
cm VAS scale (56), this effect size can be compared to the effect size of acetaminophen (-
0.14 [0.23;0.05]) or NSAIDs, which have an effect size of -0.29 [-0.35; -0.22] (57). If IAHA 
is indeed as efficient in the treatment of pain as NSAID, IAHA could be an important 
alternative for those unable to take, are intolerant of, or have contraindications for use of 
NSAIDs.   
There was no evidence, with a risk difference (RD) of 0.002 [CI -0.001; 0.005], that 
the participants in the IAHA group experienced more serious adverse events than those in the 
placebo group. The analysis of RD was a post-hoc analysis. The analysis planned in the 
protocol was a Relative Risk (RR) analysis, which gave an RR of 1.30 [CI, 0.95; 1.78]. 
Unfortunately only 17 trials contributed data to the analysis due to that the rest of the trials 
reported zero events in both study groups. An RR can therefore be argued to be inappropriate 
statistics for the available data since a vast part of the data is disregarded. Sixty-one trials in 
this meta-analysis reported SAE, and in a substantial part of these trials the reporting lacked 
transparency. It would be in the interest of health professionals and patients to get better 
evidence for the IAHA treatment in the future. This possibility could occur only if large trials 
of good methodological quality following the CONSORT statement with transparency in 
reporting regarding both efficacy and safety (58, 59) existed for analysis.  
 
This meta-analysis finds the benefit of IAHA on pain in patients with OA to be small, but 
clinically potentially relevant, reaching the minimal important difference. Guideline panels 
should, however, be aware that significant methodological issues around these findings 
reduce our confidence in the estimate. We conclude that there is low-quality evidence for the 
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use of hyaluronic acid in pain management among patients with osteoarthritis; the confidence 
in the effect estimate is limited and the true effect may be substantially different from the 
estimated effect. 
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Figure legends 
 
Figure 1  
Flow Diagram 
RCT:  Randomized controlled trial; OA: Osteoarthritis 
 
Figure 2  
Forest plot of differences in pain intensity expressed as effect size comparing the effects of any type of intra-
articular hyaluronic and sham or no intervention on pain in 85 comparisons in available trials. 
ES represents the effect size, Hedges’s ‘g’, SMD 
Blue shading represents the area of clinical equivalence smaller than minimal important difference 
 
Figure 3  
Funnel plot for effects on pain 
Area outside of the dashed line displays significant P-value >0.05 and inside the 
dashed line is nonsignificant. 
 
Figure 4 
Results of stratified analyses of pain outcomes 
Tau
2
 represents the between study variance 
P-value for interaction from test for trend 
Blue shading represents the area of clinical equivalence smaller than minimal important difference. 
 
Figure 5 
Serious Adverse Events 
Results of meta-analysis of serious adverse events in 71 trials. Note that 11 trials 
did not report serious adverse events and did not contribute to the analysis and are 
shown as ―excluded‖. 
Two trials are located from one publication (91) but report on SAE separately 
 RD: Risk Difference 
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Kn
ee 
Ortovis
c 
1000 No No 1 3 
Kotevoglu 1, 
2006 
78 Full report 
59 
3 10 26 
Kn
ee 
Orthovi
sc 
1000-
2900 
No No 1 3 
Kotevoglu 2, 
2006 
78 Full report 
59 
3 10 26 
Kn
ee 
Synvisc 6000 Yes No 1 3 
Petrella, 2006 106 Full report 
63 
3 0 12 
Kn
ee 
Suplasy
n 
730 No No 1 3 
Qvistgaard, 2006 104 Full report 
66 
4 9 13 Hip 
Hyalga
n 
500-
730 
No Yes 1 3 
Salk , 2006 20 Full report 
59 
4 8 26 
Ot
her 
Hyalga
n 
500-
730 
No No 1 5 
Strand 1 France, 
2006 
254 Full report 
65 
5 8 13 
Kn
ee 
Supartz 
620-
1170 
No No 1 5 
Strand 2 France, 
2006 
254 Full report 
65 
3 10 13 
Kn
ee 
Supartz 
620-
1170 
No No 1 3 
Strand 3 UK, 
2006 
231 Full report 
61 
5 8 25 
Kn
ee 
Supartz 
620-
1170 
No No 1 5 
Blaine 1, 2008 660 Full report 
63 
3 14 26 
Ot
her 
Hyalga
n 
500-
730 
No No 1 3 
Blaine 2, 2008 660 Full report 
63 
5 12 26 
Ot
her 
Hyalga
n 
500-
730 
No No 1 5 
Blanco, 2008 52 Full report 
68 
5 12 58 
Kn
ee 
Adant 900 No No 2 5 
Cohen, 2008 30 Full report 
50 
5 13 26 
Ot
her 
Hyalga
n 
500–
730 
No Yes 1 5 
Heyworth, 2008  60 Full report 
63 
2 10 26 
Ot
her 
Synvisc 6000 Yes No 1 2 
Lundsgard, 2008 251 Full report 
69 
4 12 26 
Kn
ee 
Hyalga
n 
500-
730 
No No 1 4 
Petrella 1, 2008 200 Full report 
 
70 
3 13 16 
Kn
ee 
NA 
580-
780 + 
1200-
2000 
No No 1 3 
Petrella 2, 2008 200 Full report 
70 
3 13 16 
Kn
ee 
NA 
500-
730 
No No 1 3 
Petrella 3, 2008 200 Full report 
70 
3 13 16 
Kn
ee 
NA 6000 Unclear No 1 3 
Sanofi-Aventis, 
2008 
159 
Unpublishe
d 
NA 
4 11 26 
Kn
ee 
Hyalga
n 
500-
730 
No No 1 3 
Altman, 2009 588 Full report 
62 
3 9 26 
Kn
ee 
Euflexx
a 
3000 No No 1 3 
Baltzer, 2009 376 Full report 
59 
2 11 26 
Kn
ee 
HYA-
Ject 
1400 No No 1 3 
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Diracoglu, 2009 63 Full report 
58 
3 1 4 
Kn
ee 
Synvisc 6000 Yes No 1 3 
Figen, 2009 33 Full report 
63 
1 23 26 
Ot
her 
Synvisc 6000 Yes No 1 1 
Migliore, 2009 42 Full report 
70 
5 8 26 Hip 
Hyalub
rix 
1500-
3200 
No Yes 1 2 
Genzyme/Sanofi 
Aventis, 2009 - 
NCT00949494 ¶ 
NA 
Unpublishe
d 
 
NA 3 10 26 
Kn
ee 
Synvisc 6000 Yes No 1 3 
Richette, 2009 85 Full report 60 1 12 13 Hip Adant 900 No Yes 1 1 
Chevalier, 2010 253 Full report 
63 
1 12 27 
Kn
ee 
Synvisc
-One 
6000 Yes No 1 1 
Colen, 2010 - 
NCT01079455 ¶ 
NA 
Unpublishe
d 
NA 
1 11 26 Hip 
Ostenil 
plus 
NA No Yes 1 1 
Jørgensen , 2010 337 Full report 
62 
5 8 52 
Kn
ee 
Hyalga
n 
500-
730 
No No 1 5 
Kosuwon, 2010 60 Abstract 
60 
5 11 26 
Kn
ee 
Go On 
800-
1500 
No No 1 5 
Kul-Panza, 2010 48 Full report 
61 
3 11 14 
Kn
ee 
Orthovi
sc 
1500 No No 1 3 
Pavelka 1, 2010 439 Abstract 
NA 
2 24 26 
Kn
ee 
HYADD
4-G 
500-
730 
No No 1 2 
Pavelka 2, 2010 439 Abstract 
NA 
3 23 26 
Kn
ee 
HYADD
4-G 
500-
730 
No No 1 3 
Tang, 2010 60 Full report 
43 
5 1 6 
Ot
her 
Sofast 
1500-
2500 
No No 1 5 
Atchia, 2011 78 Full report 
69 
1 8 8 Hip 
Durola
ne 
1000 No Yes 1 1 
Huang, 2011 200 Full report 
65 
5 8 25 
Kn
ee 
Hyalga
n 
500-
730 
No No 1 5 
Munteanu, 2011 151 Full report 
55 
1 13 27 
Ot
her 
Synvisc 6000 Yes Yes 1 1 
Navarro-Sarabia, 
2011 
306 Full report 
63 
117 30 173 
Kn
ee 
Adant 900 No No 4 5 
Meir Mecical 
Center, 2011 - 
NCT00728611 ¶ 
NA 
Unpublishe
d 
 
NA NA NA NA  
Kn
ee 
NA NA No No NA NA 
Rancitelli, 2011 31 Full report 
49 
1 11 26 
Ot
her 
NA NA No No 1 1 
Sindel , 2011 61 Abstract 
NA 
3 NA NA 
Kn
ee 
Orthovi
sc 
1000 No No 1 3 
DeCaria, 2012 30 Full report 
72 
3 13 29 
Kn
ee 
Suplasy
n 
730 No No 1 3 
Degroot, 2012 64 Full report 
57 
1 11 12 
Ot
her 
Supartz 
620-
1170 
No Yes 1 1 
Ferring 
Pharmaceuticals, 
2012 - 
NCT00988091 ¶ 
596 
Unpublishe
d 
61 
1 25 26 
Kn
ee 
NA NA No No 1 1 
Strand, 2012 379 Full report 
60 
1 12 13 
Kn
ee 
Gel-
200 
NA Yes No 1 1 
Kwon, 2013 300 Full report 
66 
2 11 26 
Ot
her 
Supartz 
620-
1170 
No No 1 3 
Fidia 
Farmaceutici, 
2013 - 
NCT01372475 ¶ 
NA 
Unpublishe
d 
NA 
NA NA 26 
Kn
ee 
Hymovi
s 
NA No No NA NA 
Arden, 2014 218 Full report 
63 
1 6 7 
Kn
ee 
Durola
ne 
1000 No No 1 1 
              
 
        
 
kDa: kilo Dalton 
 34 
US: ultra sound guidance 
NA: Not available data 
Cycles: recurring series of injections 
Follow-duration: weeks from end of treatment to follow-up assessment 
§: Publication not located or data not available in publication. Data extracted from other reviews or 
meta-analysis 
¶: No publication published, only protocol available. Data extracted from protocol 
 
 
Methodological Characteristics 
 
Author, year 
No. 
randomi
zed/ 
analyze
d 
Interven
tion 
No. 
randomi
zed/ 
analyze
d 
Control 
Sequen
ce 
genera
tion 
Alloca
tion 
conce
al-
ment 
Blindin
g of 
particip
ants 
Blindin
g of 
person
nel 
Incomp
lete 
outcom
e data 
address
ed 
Selecti
ve 
outco
me 
reporti
ng 
Overa
ll Risk 
of 
bias 
Other 
Industr
y 
support 
Mult
i 
cent
er 
Peyron (Rydell), 
1974 NA/14 NA/14 Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
Uncle
ar Unclear 
Uncl
ear 
Weiss, 1981 16/16 16/16 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Shichikawa A, 
1983 52/48 55/50 Unclear 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk Unclear Yes 
Shichikawa B, 
1983   114/96 114/102 Unclear 
Adequ
ate 
Adequa
te 
 Adequ
ate 
 Inadeq
uate 
Adequa
te 
 High 
risk 
 Inadeq
uate  Yes 
Bragantini, 1987 20/20 19/18 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Adequa
te 
High 
risk Unclear 
Uncl
ear 
  21/19                     
Grecomoro, 1987 20/20 20/18 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Dixon, 1988  § 30/NA 33/NA Unclear 
Adequ
ate 
Adequa
te 
Adequa
te Unclear 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Russell, 1992  § 70/60 69/57 Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Bertolami , 1993 37/NA 20/NA Unclear 
Adequ
ate Unclear 
Adequa
te Unclear 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Dougados, 1993 55/49 55/46 
Adequa
te 
Adequ
ate 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
Adequa
te 
High 
risk Unclear Yes 
Isdale, 1993 NA/NA NA/NA Unclear 
Unclea
r Unclear Unclear Unclear Unclear 
Uncle
ar Unclear 
Uncl
ear 
Moreland, 1993 § NA/46 NA/47 Unclear 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Pedersen, 1993 23/NA 24/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Puhl , 1993 102/95 107/100 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate Yes 
Cohen, 1994 19/NA 20/NA Unclear 
Unclea
r Unclear 
Adequa
te Unclear Unclear 
Uncle
ar 
Inadeq
uate 
Uncl
ear 
Creamer, 1994 12/12 12/12 Unclear 
Unclea
r Unclear Unclear 
Adequa
te Unclear 
Uncle
ar 
Inadeq
uate No 
Henderson, 1994 45/40 46/44 
Adequa
te 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk Unclear No 
Scale 1, 1994 25/NA 25/NA Unclear Unclea Unclear Unclear Unclear Adequa Uncle Inadeq Yes 
 35 
r te ar uate 
Scale 2, 1994 15/NA 15/NA                   
Adams, 1995 37/32 34/32 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate Yes 
Carrabba 1, 1995 20/20 20/20 Unclear 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Uncle
ar 
Inadeq
uate 
Uncl
ear 
 
20/20 
            20/20                     
Corrado. 1995 21/19 19/16 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Adequa
te 
High 
risk Unclear 
Uncl
ear 
Formiguera, 1995 20/20 20/20 
Adequa
te 
Unclea
r Unclear Unclear 
Adequa
te 
Adequa
te 
Uncle
ar Unclear 
Uncl
ear 
Guler, 1996 § 15/NA 15/NA                   
Lohmander, 1996 120/96 120/93 Unclear 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate Yes 
Kalay, 1997  § 20/NA 20/NA                   
Schneider, 1997 18/18 18/18 Unclear 
Unclea
r 
Inadequ
ate 
Inadeq
uate 
Adequa
te 
Inadeq
uate 
High 
risk 
Inadeq
uate No 
Wu  1997 62/56 54/41 Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Altman, 1998 164/109 168/123 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Wobig, 1998 57/57 60/60 Unclear 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate Yes 
Huskisson, 1999 50/39 50/41 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk Unclear No 
Renklitepe, 2000 § 10/NA 10/NA                   
Anika 
Therapeutics, 
2000  § 201/178 184/158                   
Ardic, 2001 15/15 5/5 Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
Uncle
ar 
Inadeq
uate 
Uncl
ear 
Brandt, 2001 114/66 112/69 
Adequa
te 
Adequ
ate Unclear 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Bunyaratavej, 
2001  24/NA 25/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear Yes 
Carucuel, 2001 10/NA 14/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
  13/NA                     
Dickson, 2001 53/53 57/57 Unclear 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Uncle
ar 
Inadeq
uate Yes 
Groppa, 2001 NA/NA NA/NA 
Inadeq
uate 
Unclea
r Unclear Unclear Unclear Unclear 
High 
risk Unclear 
Uncl
ear 
Tamir, 2001 25/22 24/20 Unclear 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk Unclear No 
Anika 
Therapeutics, 
2001  § 114/114 112/112                   
Bütün, 2002 28/NA 28/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Cogalgil, 2002 20/NA 20/NA Unclear 
Unclea
r 
Inadequ
ate 
Inadeq
uate Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
Hizmetli, 2002 § 25/20 25/20                   
Karlson, 2002 92/76 66/57 
Adequa
te 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
  88/77                     
Miltner, 2002 43/NA 43/NA Adequa Unclea Unclear Unclear Unclear Adequa Uncle Unclear Uncl
 36 
te r te ar ear 
Petrella 1, 2002 30/25 30/28 
Adequa
te 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate 
Uncl
ear 
Petrella 2, 2002 30/29 30/26                   
Jubb, 2003 208/208 200/200 Unclear 
Unclea
r Unclear 
Adequa
te 
Adequa
te 
Adequa
te 
Uncle
ar 
Inadeq
uate Yes 
Kahan, 2003 258/251 260/246 
Adequa
te 
Unclea
r Unclear Unclear 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Tetik , 2003 30/30 30/30 Unclear 
Unclea
r 
Inadequ
ate 
Inadeq
uate 
Adequa
te 
Adequa
te 
High 
risk Unclear No 
Tsai, 2003 NA/NA NA/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Altman, 2004 173/172 174/174 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Inadeq
uate Yes 
Day, 2004 116/108 124/115 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate Yes 
Pham, 2004 131/131 85/85 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk Unclear Yes 
Wu, 2004 30/30 30/30                   
Genzyme, 2005 § 52/NA 50/NA                   
Cubukcu, 2005 30/30 10/10 Unclear 
Unclea
r Unclear Unclear 
Adequa
te 
Adequa
te 
High 
risk Unclear No 
Neustadt, 2005 
 
128/115 
120/107 
124/114 
124/114 
Adequa
te 
 
Adequ
ate 
 
Adequa
te 
 
Adequa
te 
 
Inadeq
uate 
 
Adequa
te 
 
High 
risk 
 
Inadeq
uate 
 
Yes 
 
Rolf, 2005 90/90 91/91 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
  91/91                     
Sezgin, 2005 22/NA 19/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Adequa
te 
Uncle
ar Unclear No 
Kotevoglu, 2006 NA/20 NA/18 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
  NA/21                     
Petrella, 2006 53/53 53/53 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk 
Inadeq
uate No 
Qvistgaard, 2006 34/33 36/36 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Inadeq
uate No 
Salk, 2006 NA/9 NA/8 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Strand 1 France, 
2006 NA/87 NA/80 
Adequa
te 
Unclea
r Unclear 
Adequa
te Unclear 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Strand 2 France, 
2006 NA/87                     
Strand 3 UK, 2006 NA/116 NA/115 
Adequa
te 
Unclea
r Unclear 
Adequa
te Unclear 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Blaine, 2008 218/197 221/204 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate Yes 
  221/201                     
Blanco, 2008 26/22 26/20 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate No 
Cohen, 2008 16/15 14/13 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Uncle
ar 
Inadeq
uate 
Uncl
ear 
Heyworth, 2008  20/20 18/18 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk 
Inadeq
uate No 
Lundsgard, 2008 84/82 84/80 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Adequa
te No 
Petrella, 2008 50/50 50/50 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk 
Adequa
te Yes 
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50/50 
            50/50                     
Sanofi-Aventis, 
2008 79/69 80/70 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Altman, 2009 293/291 295/295 
Adequa
te 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate Unclear 
High 
risk 
Inadeq
uate Yes 
Baltzer, 2009 135/135 107/107 
Inadeq
uate 
Adequ
ate Unclear 
Adequa
te 
Adequa
te 
Adequa
te 
High 
risk 
Adequa
te Yes 
Diracoglu, 2009 42/40 21/20 
Adequa
te 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk Unclear No 
Figen, 2009 33/29 33/29 
Adequa
te 
Unclea
r Unclear Unclear 
Adequa
te 
Inadeq
uate 
High 
risk 
Adequa
te 
Uncl
ear 
Migliore, 2009 22/NA 20/NA 
Adequa
te 
Unclea
r 
Adequa
te 
Adequa
te Unclear 
Adequa
te 
Uncle
ar 
Inadeq
uate No 
Genzyme/Sanofi 
Aventis, 2009 - 
NCT00949494                       
Richette, 2009 42/42 43/43 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Inadeq
uate Yes 
Chevalier, 2010 124/124 129/129 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Inadeq
uate Yes 
Colen, 2010 
NCT01079455                       
Jørgensen, 2010 167/165 170/170 Unclear 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate Unclear 
High 
risk 
Inadeq
uate Yes 
Kosuwon, 2010 30/NA 30/NA Unclear 
Unclea
r Unclear Unclear Unclear Unclear 
Uncle
ar Unclear 
Uncl
ear 
Kul-Panza, 2010 25/23 23/22 
Adequa
te 
Unclea
r Unclear 
Adequa
te 
Inadeq
uate 
Adequa
te 
High 
risk Unclear No 
Pavelka, 2010 145/NA 144/NA Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
  150/NA                     
Tang, 2010 20/20 20/20 Unclear 
Unclea
r 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk Unclear No 
Atchia, 2011 19/19 19/19 
Adequa
te 
Unclea
r 
Adequa
te 
Adequa
te Unclear 
Inadeq
uate 
Uncle
ar 
Inadeq
uate Yes 
Huang, 2011 100/100 100/98 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Munteanu, 2011 75/75 76/76 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Inadeq
uate Yes 
Navarro-Sarabia, 
2011 153/149 153/152 
Adequa
te 
Adequ
ate Unclear 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
Meir Mecical 
Center, 2011 - 
NCT00728611                       
Rancitelli, 2011  NA/NA NA/NA 
Inadeq
uate 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk 
Adequa
te 
Uncl
ear 
Sindel , 2011 34/34 27/27 Unclear 
Unclea
r Unclear Unclear Unclear 
Inadeq
uate 
High 
risk Unclear 
Uncl
ear 
DeCaria, 2012 15/15 15/15 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Adequa
te No 
Degroot, 2012 39/39 25/25 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk Unclear Yes 
Ferring 
Pharmaceuticals, 
2012 - 
NCT00988091 298/294 298/295 Unclear 
Unclea
r Unclear Unclear 
Inadeq
uate 
Adequa
te 
High 
risk 
Inadeq
uate 
Uncl
ear 
Strand, 2012 251/247 128/128 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Inadeq
uate 
Inadeq
uate 
High 
risk 
Inadeq
uate Yes 
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Kwon, 2013 150/150 150/150 Unclear 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Inadeq
uate 
High 
risk Unclear Yes 
Fidia 
Farmaceutici, 
2013 - 
NCT01372475                       
Arden, 2014 108/108 110/110 
Adequa
te 
Adequ
ate 
Adequa
te 
Adequa
te 
Adequa
te 
Adequa
te 
Low 
risk 
Inadeq
uate Yes 
 
 
NA: Not available data 
§: Number of patients not available in publication. Data extracted from other reviews or 
meta-analysis 
 
 
 
